



ALK  
Investor Relations Department  
BÃge Alle 6-8  
Horsholm DK-2970  
Denmark

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### OMX: ALKB

|               |  |
|---------------|--|
| Last Trade:   | 791.00   |
| Trade Time:   | 4:59 PM ET<br>Jan 22, 2018                         |
| Change:       | -3.00 <span style="color: red;">↓</span> (-0.378%) |
| Day Range     | 790.00 - 798.00                                    |
| 52-Week Range | 681.00 - 1133.00                                   |
| Volume        | 1,378,600  |

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

## Company releases [\[ View all \]](#)

*Dec 20, 2017*

[ALK — Financial calendar for the 2018 financial year](#)

*Dec 11, 2017*

[Reporting of transactions with ALK-Abelló A/S' B-shares and associated securities by person closely associated with person discharging managerial responsibly](#)

*Dec 11, 2017*

[Indberetning af transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer udført af personer med nær tilknytning til personer med ledelsesansvar](#)

*Dec 11, 2017*

[REGISTRATION OF CAPITAL INCREASE OF DKK 92,076 AA SHARES AND DKK 920,760 B SHARES BY THE ISSUE OF NEW SHARES COMPLETED](#)

*Dec 7, 2017*

[Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff](#)

## Upcoming Events [\[ View all \]](#)

*Feb 6, 2018*

[Annual report 2017](#)

*Mar 12, 2018*

[AGM](#)